{"id":"W2949515538","doi":"10.1016/j.ejca.2019.05.008","title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Foundation Medicine; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Open label; Cancer; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007201812,0.000434122,0.001013154,0.000121532,0.0001285895,0.0001001373,0.0004069027,0.00005223063,0.0008977606],"category_scores_gemma":[0.00006529102,0.0002537663,0.0002162736,0.0002954858,0.0000845087,0.0002331498,0.00004723295,0.0003527733,0.00001008469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084008,"about_ca_system_score_gemma":0.001481649,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004202113,"about_ca_topic_score_gemma":0.0008734255,"domain_scores_codex":[0.9967621,0.0002604862,0.001490563,0.0004507583,0.0006622167,0.0003738664],"domain_scores_gemma":[0.9969842,0.0003575607,0.00168596,0.0004501919,0.000351438,0.0001706387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9424196,0.00091094,0.0004922486,0.00001894729,0.002007097,0.0006720239,0.003631574,0.003062141,0.00614513,4.482654e-7,0.0006068337,0.04003297],"study_design_scores_gemma":[0.9665295,0.009960557,0.004053315,0.0007655171,0.0006345913,0.00003729578,0.0006001304,0.0004394968,0.00538084,0.000001729085,0.01126731,0.0003296897],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851326,0.003748845,0.00002158456,0.004651016,0.001797335,0.003218716,0.0001337003,0.00001718787,0.001278993],"genre_scores_gemma":[0.9915171,0.003297584,0.0003180561,0.0008506452,0.0007401135,0.0001060825,0.00006432585,0.00009914552,0.003006929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03970328,"threshold_uncertainty_score":0.9999915,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02583722178502796,"score_gpt":0.3212381747489892,"score_spread":0.2954009529639613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}